Our data support the premise that there is a unique synergistic vulnerability exposed by combining BET and MEK inhibitors, and that this combination could be used as a salvage strategy for targeted‐ and immune checkpoint inhibitor‐resistant melanoma. The gene discussed is MAP2K7; the disease is melanoma.